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The targeted design of nanoparticles for efficient drug loading and defined release profiles is 
even after 25 years of research on lipid-based nanoparticles still no routine procedure. It 
requires detailed knowledge about the interaction of the drug with the lipid compounds and 
about its localisation and distribution in the nanoparticle. We present here an investigation on 
nano-sized lipid particles (NLP) composed of Gelucire and Witepsol as solid lipids, and 
Capryol as liquid lipid, loaded with Dexamethasone, a glucocorticoid used in topical treatment 
of inflammatory dermal diseases. The interactions of Dexamethasone, which was spinlabelled 
by 3-(Carboxy)-2,2,5,5-tetramethyl-1-pyrrolidinyloxy (DxPCA), with its microenvironment is 
monitored by EPR spectroscopy at 94 GHz at low temperatures. The mobility of the spin-
labelled drug was probed by X-band EPR at room temperature. In order to relate the magnetic 
and dynamic parameters deduced from EPR to the local environment of the spin probe in the 
NLP, investigations of DxPCA in the individual lipid compounds were carried out. The 
magnetic parameters reflecting the polarity of DxPCA’s environment as well as the parameters 
describing the mobility of the drug reveal that in the case of colloidal dispersions of the lipids 
and also the NLP DxPCA is attached to the surface of the nanoparticles. Although the lipophilic 
drug is almost exclusively associated to the NLP in aqueous solution, dilution experiments 
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Colloidal systems like suspensions, emulsions and micellar or vesicular solutions are in common use 
for the topical application of pharmaceuticals with limited water solubility[1]. As an alternative to 
oil/water emulsions and liposomes,  lipid-based nanoparticles have been introduced as drug delivery 
systems for poorly water-soluble drugs [2, 3]. These nanoparticles have potential advantages over 
liposomes and emulsions: They show room/body temperature stability, no organic solvents are needed 
throughout preparation, a broad application spectrum, and the controlled release of the incorporated 
drug is possible [4, 5]. Additionally the composition of nanoparticles from different lipids and 
surfactants allows for tuning to different drug solubilities [4, 6, 7]. 
Lipid-based nanoparticles can be classified into solid lipid nanoparticles (SLN) or heterogeneous, 
presumably liquid/solid phase matrix particles, called nanostructured lipid carriers (NLC). NLC were 
developed to increase the loading capacity compared to SLN [4]. A number of investigations concerning 
the size and shape of SLN and NLC has been published [8, 9]. Either a crystalline or supercooled melt 
matrix core is found, depending on the compositions [8-10]. 
Investigations concerning the drug distribution within the nanoparticles are rare [10, 11]. One report 
made use of model compounds like the fluorescent nile red and found a localisation in the oily phase of 
NLC [12]. Diverging models assume the inclusion of substrates either in the core, the outer shell, as a 
colloidal dispersion in the lipid matrix or in a homogeneous distribution [13, 14]. It is generally accepted 
that lipid-based nanoparticles including NLCs improve the penetration of drugs through the skin  [5, 15, 
16]. 
For the treatment of inflammatory diseases and in particular dermal diseases Dexamethasone (Dx) is 
regularly used [17]. It is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive 
effects [17]. Due to its low solubility in water (89 mg/l at 25 °C) co-solvation or usage of liquid lipids 
is necessary. 
Electron paramagnetic resonance (EPR) is a well-established method for probing the local environment 
of a spin probe with respect to polarity, proticity and mobility [18, 19]. NO-based spin labels have been 
used as probes in membrane proteins  [20, 21], lipids [18, 19]]  and liposomes [22, 23]. EPR can 
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furthermore provide information on the loading of molecules onto, localisation in and release from nano-
sized carrier systems [11, 24-26].  
In the present study, multi-frequency EPR was used to determine the microenvironment of the spin-
labeled Dx within lipid-based carrier systems to elucidate the localisation of the drug within the carrier. 
Control measurements were performed on different sizes of the NLP, on its individual compounds and 
mixtures at room temperature and under cryogenic conditions (80 K). Furthermore, dilution experiments 





Material and Methods 
Preparation of spin-labelled dexamethasone (DxPCA) 
DxPCA was synthesized by refluxing Dx with PCA, 4-(Dimethyl)-aminopyridin and 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide in dichloromethane for 3h with subsequent column-
chromatographic purification [27]. 
 
Synthesis of nano-sized lipid particles (NLP)  
The lipid components Gelucire® 50/13 (stearoyl macrogolglycerides,GATTEFOSSÉ GmbH, Bad 
Krozingen, Germany), Witepsol® S55 (solid triglycerides containing hydrogenated coco-glycerides, 
beeswax and ceteareth-25, CREMER OLEO GmbH & Co. KG, Hamburg, Germany), and Capryol® 90 
(propylene glycol monocaprylate, Gattefossé GmbH, Bad Krozingen, Germany)  were mixed in a ratio 
of 5:3:1 (w/ w) and melted at 60°C together with 0.5% (w/ w) PCA-labeled Dx. The 10% (w/ w) lipid 
nanosuspension was prepared from a nanoemulsion by pouring ultrapure water of the same temperature 
to the lipid melt and high-shear-homogenization for 5 minutes. Finally, the nanoemulsion was cooled to 
room temperature to solidify the lipid phase and thus, to obtain the lipid nanosuspension. The lipid 
nanosuspension was filtered through 0.7 µm glass fiber filters (Whatman® GF/F; Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) to eliminate precipitated drug crystals from the water phase.  
Two different sizes of DxPCA loaded NLP were produced to study the effect of loading. Furthermore, 
DxPCA was incorporated into single lipid components of the NLP and in selected lipid combinations, 
with and without dispersion in water to associate the microenvironment of DxPCA in the NLP. 
 
Particle size determination 
 
 
The mean particle size of the NLP was determined by a Zetasizer® Nano ZS (Malvern Instruments 
GmbH, Herrenberg, Germany) equipped with a He-Ne laser (633 nm) at a backscattering angle of 173°C 
and cell temperature of 25°C. The lipid nanosuspension was diluted to a ratio of 1:10 (v/v) with ultrapure 
water. 10 runs were performed, from which the mean particle size and polydispersity index with standard 
deviation was calculated. The particle size of the DxPCA NLP is 134 ± 3 and 242 ± 18 nm, respectively. 
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To investigate the release behaviour of DxPCA, dilution series were performed: a NLP solution (NLP 
diameter: 134 nm ± 3 nm) loaded with DxPCA was diluted to ratios of 1:10 and 1:50 with water, 
followed by measurements with a Zetasizer® Nano ZS.  
 
Electron paramagnetic resonance (EPR) spectroscopy 
Cryogenic temperature (80K) EPR measurements were performed using a W-band (94 GHz) EPR 
spectrometer (Bruker Elexsys E680 S/W-Band) equipped with a Teraflex EN600-1021H probe head 
(Bruker Biospin, Karlsruhe, Germany). Room temperature measurements at X-band (9 GHz) were 
performed on a lab-built spectrometer employing a SHQ probe head (Bruker Biospin, Karlsruhe, 
Germany). The temperature was monitored by an Oxford ITC 503 temperature controller. The magnetic 
field was calibrated using a N@C60 standard [28]. 
For all cryogenic measurements the samples were prepared in quartz tubes of 0.87/0.7 mm (outer 
diameter (o.d.)/inner diameter (i.d.) (VitroCom Inc, Mountain Lakes, USA) for W-band. Room 
temperature EPR at X-band was performed with 2 mm/1mm (o.d./i.d.)  capillaries. The experimental 
parameters are different for each microwave band and are shown in the respective figure legend. 
The evaluation of the magnetic parameters (g-matrix, 14N hyperfine couplings, rotational correlation 
time and line width) for determining the environment polarity and mobility of DxPCA was performed 
using the EasySpin toolbox [29], a Matlab package (The MathWorks GmbH, Ismaning, Germany) for 







Localisation of DxPCA within the NLP  
 
DxPCA was investigated in NLP and in different lipid-solutions of the NLP components by X-band (9.4 
GHz) and W-band (94 GHz) at room temperature and at 80 K to evaluate the microenvironment 
properties polarity and viscosity, and the mobility of the drug in the used carrier system.  
The g-matrix principal value gxx and the 14N hyperfine coupling parameter Azz are sensitive to the 
polarity and proticity of the microenvironment of a nitroxide compound [30, 31]. To study the g-matrix 
and 14N hyperfine coupling, DxPCA loaded to NLP  was investigated by high frequency (W-band) EPR 
spectroscopy at 80 K (Figure 1). Figure 1 shows the low temperature spectra of DxPCA in aqueous 
dispersions of Gelucire/Witepsol, in NLP (242 nm), in the liquid lipid Capryol, and of DxPCA dissolved 
in water. Additionally EPR spectra of DxPCA in Gelucire, Witepsol, Gelucire/Witepsol mixture and 
Gelucire/water dispersion were recorded and are shown in Figure S1. Water was chosen as a reference, 
since it acts as the solvent surrounding the NLP and has one of the highest polaritiy and proticity 
properties [32]. The g-matrix and the 14N hyperfine coupling matrix A of DxPCA in the different 
mixtures/solvents were evaluated by simulation of the experimental spectra and are given in Table 1. 
Thereof, the principal components gxx and Azz are most sensitive to the solvent properties’ polarity and 
proticity which are indicated in Figure1. 
Table 1 Magnetic interaction parameters of DxPCA in NLP, water and different lipids 
DxPCA surrounded by g-matrix 
principal values (SD) 
Hyperfine Coupling (hfc) 
(MHz) 
 gxx gyy gzz Axx Ayy Azz 
water 2.0081(2) 2.0060(2) 2.0021(5) 14 13 104 
NLP  (242nm) 2.0085(3) 2.0060(2) 2.0021(1) 15 15 99 
Gelucire 2.0090(3) 2.0062(3) 2.0021(2) 13 13 95 
Witepsol 2.0090(5) 2.0062(4) 2.0021(3) 12 10 95 
Capryol 2.0087(2) 2.0061(5) 2.0021(4) 13 13 98 
Gelucire(water) 2.0088(4) 2.0062(3) 2.0022(2) 14 12 97 
Gelucire/Witepsol 2.0090(2) 2.0062(5) 2.0021(2) 12 13 95 
10 
Gelucire/Witepsol(water) 2.0086(5) 2.0061(5) 2.0021(5) 14 15 98 
 
 
The gxx- and Azz-values of DxPCA in water are typical for a spin label in an aqueous environment [31]. 
All gxx-values for DxPCA in the lipids are upshifted and all Azz are downshifted compared to the water 
solution, as expected for these more lipophilic and less protic environments. DxPCA in the solid lipids 
display the most upshifted gxx- and downshifted Azz-values. DxPCA in the NLP shows values almost 
identical to those in the liquid lipid Capryol or in a Gelucire/Witepsol mixture dispersed in water. 
Interestingly, the g-values and 14N-hfc for DxPCA depend strongly on the type of preparation. In the 
pure lipids Gelucire and Witepsol or the Gelucire/Witepsol mixture (Fig S1), the magnetic parameters 
are shifted towards lower polarity, whereas in the aqueous dispersions of these lipids a clear trend of a 
shifts towards higher polarity is seen (Table 1). Thus, the spin-labelled drug apparently has to be located 
in the lipid nanoparticles in an environment such that the magnetic parameters are influenced by the 
polarity of water.  
The line shape of room temperature (rt) X-band EPR spectra encodes the mobility of a spin label, here 
the spin-labelled drug DxPCA, and thereby reports on the viscosity of its environment (Figure 2, Figure 
S2). The mobility can be parameterized under the assumption of isotropic rotation by the rotational 
correlation time (tcorr).  This parameter was evaluated by simulation of the rt-EPR spectra (dashed lines). 
Figure 2 shows a comparison of rt X-band EPR of DxPCA in water, NLP and selected individual lipid 
compounds. Further spectra in other lipids and lipid mixtures are shown in Figure S2.  
The rt-EPR spectrum of DxPCA dissolved in water is composed of two components, a spectrum 
consisting of three narrow lines, and a broad unstructured spectrum underneath the middle line of the 
narrow line spectrum (Figure 2, last spectrum). The solubility of DxPCA in water is quite limited 
(approx. 2 µmol/l  at rt, see also information given in the ESI) and DxPCA is presumably partially 
aggregated in aqueous solution [33]. The broad spectrum can be attributed to such an aggregated DxPCA 
fraction (see also [34] for further details). The narrow-line spectrum can be assigned to the dissolved 
DxPCA fraction. The tcorr of the free DxPCA in water derived from the spectrum is approximately 90 
ps. DxPCA in NLP shows a superposition of a spectrum with three broadened lines, indicating a 
11 
significantly lower mobility of DxPCA (tcorr=3.2 ns) [35], and of a minority of free DxPCA directly 
visible only as a narrow feature at 336.5 mT, The free DxPCA component accounts for only approx. 2 
% of the overall intensity. In the liquid lipid Capryol (Figure 2, second spectrum from top) DxPCA is 
tumbling slower (tcorr ≈ 1.3 ns) than in water, but significantly faster than in the other lipids. The rt-EPR 
spectrum for DxPCA in the solid Gelucire/Witepsol mixture (Figure 2, top spectrum) is similar to those 
in the individual lipids (see Figure S2). Interestingly, the rt-EPR spectra of DxPCA in a 
Gelucire/Witepsol dispersion in water (Gelucire/Witepsol(water)) resembles starting from the central 
peak to the high-field end closely the spectrum observed for the NLP case. The low field side of the 
Gelucire/ Witepsol spectrum shows two components, one that again closely resembles the spectral shape 
found for DxPCA in NLP and one arising from a more immobilized fraction (low field peak).  The main 
component of the spectrum can be approximated by a simulation with a single component (tcorr=4.5 ns).  
In order to analyze whether the NLP size has an effect on the loading with DxPCA, two batches with 
different sizes (134 and 242 nm) have been investigated. Figure S4 shows the X-band rt-EPR spectra of 
these NLP sizes at identical NLP concentrations. The sample with the 134 nm NLP shows a signal 
intensity increase by a factor of 1.8 compared to the 242 nm NLP, matching the change of surface to 
volume ratio of the NLP due to the size change. This is a clear evidence, that the DxPCA molecules are 
associated with the surface of the nanoparticles. 
The release of DxPCA from the nanoparticles was studied in a dilution series of NLP in water (Figure 
S5). With increasing dilution the linewidth of the low field and the high field peak becomes narrower. 
Already in the undiluted sample, but most prominent at 1:10 a splitting of the high-field peak into a 
broad and a narrow component can be seen. The narrow peak increases in intensity with increasing 
dilution, whereas the broad peak is disappearing. Comparing the narrow-line component with the 
DxPCA spectrum in water, it becomes clear that this narrow component represents free DxPCA in 
solution. This indicates an equilibrium between DxPCA associated with the NLP and free DxPCA in 
solution. With increasing dilution the DxPCA dissociates from the NLP, thereby reestablishing this 
solvent equilibrium as reflected by the increase of the narrow component relative to the broad one (see 
Figure S5). A disintegration or decay of the NLP by the dilution has been excluded by size determination 







The magnetic interaction parameters gxx- and Azz obtained by W-band EPR at 80 K (Figure 1, Table 1), 
which report on the polarity of the spin labelled drug’s microenvironment, show that DxPCA loaded to 
NLP experiences an environment of higher polarity than when dissolved in bulk solid lipids. An 
environment of similar polarity as for NLP was found for DxPCA in the liquid lipid Capryol, but also 
as when investigated in Gelucire/Witepsol dispersed in water (Table 1). The higher polarity reported for 
DxPCA in the NLP compared to the bulk solid lipids could be due to an exclusive localisation of DxPCA 
in the Capryol fraction of the NLP. However, this explanation is excluded for DxPCA in the 
Gelucire/Witepsol particles dispersed in water.  At least for the Gelucire/Witepsol particles, but 
eventually also for the NLP, the reported increased environment polarity for DxPCA evidences an 
influence of water on the magnetic parameters. This could occur either by water incorporated into the 
nanoparticles due to the substantial amount of polar side chains of Gelucire (OHV=36-56) and Witepsol 
(OHV=50-65) or by a localisation of DxPCA outside the nanoparticle core at the lipid-water interface 
at the surface of the particles. A distinction between these two scenarios is impossible based on the 
effective environment polarity alone.   
The distinction whether DxPCA in NLP is in an environment dominated by Capryol or, as in the case 
of the Gelucire/Witepsol particles, in an environment strongly influenced by water can be made when 
regarding the DxPCA mobility in the different compounds. The difference in DxPCA mobility is best 
seen in the rt-X-band spectra by the broadening of the high field peak. The EPR spectra show a distinctly 
reduced mobility of DxPCA in NLP compared to the pure liquid lipid Capryol (Figure 2). This excludes 
the Capryol fraction as a potential environment of DxPCA within the NLP. Thus, the higher environment 
polarity seen by DxPCA in NLP compared to the solid lipids must have the same origin as for the 
Gelucire/Witepsol particles dissolved in water.  
The DxPCA mobility can again be used to distinguish between the possible effect of water incorporated 
into the NLP and the Gelucire/Witepsol particles, or a localisation of DxPCA at the water-exposed 
particle surface. In case of an effect by incorporated water a similar mobility of DxPCA in the bulk solid 
lipids, NLP and Gelucire/Witepsol(water) would be expected. However, a much higher mobility of 
DxPCA in NLP than in the bulk solid lipids is found (Figures 2 and S3) while rather similar mobility is 
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seen for NLP and Gelucire/Witepsol(water). The slightly higher mobility of DxPCA in NLP than in 
Gelucire/Witepsol(water) might be due to a softening of the NLP by Capryol. Thus, the observed 
DxPCA mobility clearly argues against an effect of water incorporated into the NLP as origin of the 
higher environment polarity experienced by the spin-labelled drug. Taken together the polarity and 
mobility information leads to the conclusion of a DxPCA location in the outer shell of the NLP. 
This conclusion on the DxPCA location in the NLP is corroborated by comparison differently sized 
NLP (242 nm vs 134 nm) (Figure S3). The smaller particles showed about a two times higher loading 
capacity of DxPCA per volume, which fits well to the increased surface area-to-volume ratio of 1.8 
(scaling with the inversely with the particle size).  
Sivaramakrishnan et al. (2004) also demonstrated that glucocorticoids loaded to lipophilic carrier 
systems are more likely to adhere to the particle surface than to the inner lipid matrix [36]. Furthermore, 
energy dispersive X-ray analysis has shown that Dx, if loaded to lipid particles, is partially localized at 
the particle surface [37]. In addition, the dilution experiments of the two NLP batches showed a 
complete release of DxPCA (Figure S4) by establishing the solution equilibrium between solvent and 





The study of DxPCA in the individual compounds of NLP has revealed a remarkable dependence of the 
microenvironment polarity on the lipid formulation.  A colloidal dispersion of the solid lipids in water, 
which were loaded before dispersion with DxPCA, increases the effective polarity of the environment 
experienced by the spin-labelled drug. In addition, the mobility of DxPCA differs in the individual 
lipids, lipid dispersions and the NLP. In the liquid lipid Capryol a rather high mobility of DxPCA is 
found, while a strong immobilization is found in the pure solid lipids. For NLP and the lipid dispersions 
an intermediate mobility is observed. 
Even though the effective environment polarity experienced by DxPCA is compatible with a solvation 
by the liquid lipid Capryol within the NLP this can be excluded on the basis of the differing mobility. 
Important corroboration of this conclusion has been provided by studies on dispersions of solid lipid 
mixtures without Capryol as reference systens, which show similar effective polarity and mobility as 
the NLP. 
 Taken together the polarity and mobility studies by multi-frequency EPR at room and cryogenic 
temperatures strongly argue for a location of DxPCA at the surface of the NLP at the lipid-water 
interface. Therefore, caution has to be taken in EPR investigations just concluding from the mobility 
and polarity of a spin label being localised in a specific phase of a mixture without a proper reference 
system, since surface properties may influence the spin labels magnetic and dynamic properties in a 
dominant way. 
The high pressure homogenisation apparently does not lead to the inclusion of DxPCA in the lipid 
matrix, which indicates an ordered matrix and expulsion of DxPCA to the surface during the preparation 
process. 
Nevertheless, DxPCA is almost completely associated to the NLP and shows a NLP/water equilibrium 
distribution balanced towards the nanoparticles reflected by the rt-EPR of the undiluted NLP 
preparation, where only 2% free compound in aqueous solution could be found. This is probably 
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Figure 1  
Cryogenic Temperature EPR Spectra at 80 K for DxPCA measured at W-band in different components/ 
solutions (solid line: experiment, dashed line: simulation): Gelucire/ Witepsol(water), Capryol, NLP 
solution (242 nm) and DxPCA(water); exp. Parameters:  field-swept echo spectra, pseudo modulation 5 
















Figure 2  
X-band EPR spectra of DxPCA in NLP, in individual lipids and water at room temperature (Solid line: 
experiment, dashed line: simulation); experimental parameters for the different formulations: 














Table S1  
Physical properties of unlabeled and spin-labelled Dexamethasone 
 Dexamethasone Dexamethasone-PCA 
Molecular weight [g/mol] 392.47 578.7 








Chemical structures of (A) Dexamethasone and (B) PCA-spinlabelled Dexamethasone (MPCA=186.23 
g/mol). 
  
                                               





EPR spectra of DxPCA  at 80 K in different lipid compositions  at W-band, solid line: experiment, 
dashed  line: simulation , exp. parameters: Gelucire/ Witepsol, Witepsol and Gelucire) field sweep 
echo, pseudo modulation amplitude 5 G, Gelucire(water): microwave power 5 nW,modulation 






X-band EPR spectra of DxPCA in NLP, in individual lipids and lipid mixtures dispersed in  water at 
room temperature; experimental parameters for the different formulations: microwave power 1.0 mW, 






X-band EPR spectra of DxPCA loaded to NLP with different sizes (242 nm ± 18 nm, 134 nm ± 3 nm) 
at room temperature. A) unscaled spectra from solutions of the same concentration (100 mg/ml); B) 
scaled EPR spectra, which show the same lineshape for both particle sizes. exp. parameters: modulation 








X-band EPR spectra DxPCA loaded to NLP after dilution with aqueous solution (Dilution steps: 1:10, 
1:50, 1:100, 1:200) at room temperature. All X-band EPR spectra were scaled to the size of spectrum 
without dilution. exp. parameters: modulation frequency 100 kHz, modulation amplitude 2 G, 






Dynamic light scattering measurements of DxPCA loaded NLP after dilution with water, A) Size 
distribution of the NLP after a dilution 1:10 with aqueous solution; B) Size distribution of NLP after a 
dilution 1:50 with aqueous solution. 
